Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Research and Innovation Action · Running

CAREPATH Collaborative Action and Research for Engagement, Persistence and Adherence in Treatment & Health

Coordinator
Rise Research Institutes of Sweden AB, Sweden
Runs
1 May 2025 to 30 April 2030
Status
Running
EU funding
€11.3m
Total cost
€19.8m
Partners
46 organisations in 14 countries
Type
Research and Innovation Action
Grant agreement
101192133

What the project is doing

In the project's own words, from its summary on CORDIS.

CAREPATH aims to improve chronic disease management and medication persistence by transforming the care ecosystem, ensuring personalised support for better health outcomes, and reducing healthcare costs. We focus on improving medication adherence and persistence for three prevalent chronic conditions: Obesity (BMI ≥ 30 kg/m2), Type 2 Diabetes Mellitus (T2DM), and cardiovascular diseases (CVD), including chronic heart failure (CHF), across six diverse European countries: Germany, Israel, the Netherlands, Poland, Spain, and Sweden.

These countries represent various EU healthcare environments and economic statuses, emphasising the need for tailored approaches to patient care. Our strategy involves integrating localised non-digital and digital health solutions to address the unique healthcare delivery challenges in each region. The CAREPATH toolbox collects, combines, and customises existing solutions into adaptable modules for broad application in both primary and secondary care settings.

This toolbox will be tested in four studies across two settings in all six countries in both primary and secondary care. Three pilot studies in different regions as well as a proof-of-concept study in Germany will be conducted. This comprehensive evaluation, including HTA, aims to assess the toolbox's implementation and effectiveness, with a strong focus on learning what works for what groups of patients in which setting.

Recognizing the significant impact of obesity, particular emphasis is placed on treatment adherence and persistence of medications that facilitate weight loss, such as dual GIP/GLP-1 receptor agonists, but CAREPATH studies also include patients using lipid-lowering drugs, insulin, and SGLT2 inhibitors. Our goal is to empower patients by improving communication and data sharing among patients, healthcare providers, and other stakeholders, thereby supporting the entire ecosystem and alleviating the burden on healthcare systems.

Topics

Who is involved

OrganisationCityCountryRole
Rise Research Institutes of Sweden ABBorasSwedenCoordinator
Hl7 EuropeBruxelles / BrusselBelgiumParticipant
Menarini BeneluxMachelenBelgiumAssociatedpartner
Iqvia AGRotkreuzSwitzerlandParticipant
Abbott GmbHWiesbadenGermanyParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Eberhard Karls Universitaet TuebingenTuebingenGermanyParticipant
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyParticipant
Landschaftsverband RheinlandKolnGermanyParticipant
Lilly Deutschland GmbHBad HomburgGermanyAssociatedpartner
Technische Universitaet DresdenDresdenGermanyParticipant
Universitaet LeipzigLeipzigGermanyParticipant
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-UniversitatWurzburgGermanyParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Asociación Bariátrica Híspalis NacionalSantanderSpainParticipant
Fundacio Institut D'investigacio Sanitaria Illes BalearsPalmaSpainParticipant
Fundacio Institut Universitari Pera La Recerca a L'atencio Primaria De Salut Jordi Gol I GurinaBarcelonaSpainThird party
Institut Catala De La SalutBarcelonaSpainParticipant
Institut De Investigacio En Ciencies De La Salut Germans Trias I PujolBadalona BarcelonaSpainThird party
Pfizer SLUMadridSpainAssociatedpartner
Biocorp ProductionIssoireFranceParticipant
Institut De Recherches Internationales ServierGif-Sur-YvetteFranceParticipant
Lilly FranceNeuilly-sur-Seine CedexFranceAssociatedpartner
Servier Affaires MedicalesSuresnesFranceAssociatedpartner
Servier InternationalSuresnesFranceAssociatedpartner
The European Coalition for People Living with Obesity Company Limited by GuaranteeDublinIrelandParticipant
Bar Ilan UniversityRamat GanIsraelParticipant
Israel Diabetes AssociationRishon LezyionIsraelParticipant
A. Menarini - Industrie Farmaceutiche Riunite SRLFirenzeItalyAssociatedpartner
Menarini Ricerche SpAPomeziaItalyParticipant
Academisch Ziekenhuis GroningenGroningenNetherlandsParticipant
Imagine AI B.V.UtrechtNetherlandsParticipant
Mama Producties BVEindhovenNetherlandsParticipant
Rijksuniversiteit GroningenGroningenNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stichting VuAmsterdamNetherlandsParticipant
Wavy Assistant BVGroningenNetherlandsParticipant
Ogolnopolskie Stowarzyszenie Pacjentow ze Schorzeniami Serca i Naczyn EcoserceMiloscPolandParticipant
Thaumatec SP ZOOWroclawPolandParticipant
Uniwersytet Medyczny W LodziLodzPolandParticipant
Riksforbundet HjartLungStockholmSwedenParticipant
Vastra GotalandsregionenVanersborgSwedenParticipant
Pfizer LimitedSandwichUnited KingdomAssociatedpartner
Pfizer R&D UK LimitedSandwichUnited KingdomAssociatedpartner
Eli Lilly and CompanyIndianapolisUnited StatesParticipant
Pfizer IncNew York CityUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI